Codexis Stock Forecast, Price & News

-0.24 (-1.21 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume767,355 shs
Average Volume608,490 shs
Market Capitalization$1.27 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CDXS News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

Codexis logo

About Codexis

Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.66 out of 5 stars

Medical Sector

390th out of 2,100 stocks

Industrial Organic Chemicals Industry

13th out of 40 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Codexis (NASDAQ:CDXS) Frequently Asked Questions

Is Codexis a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Codexis stock.
View analyst ratings for Codexis
or view top-rated stocks.

What stocks does MarketBeat like better than Codexis?

Wall Street analysts have given Codexis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Codexis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Codexis' next earnings date?

Codexis is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Codexis

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) announced its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.06. The biotechnology company earned $18 million during the quarter, compared to the consensus estimate of $14.85 million. Codexis had a negative trailing twelve-month return on equity of 19.58% and a negative net margin of 35.11%. The business's quarterly revenue was up 23.3% compared to the same quarter last year.
View Codexis' earnings history

How has Codexis' stock been impacted by Coronavirus?

Codexis' stock was trading at $10.12 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CDXS shares have increased by 94.1% and is now trading at $19.64.
View which stocks have been most impacted by COVID-19

What guidance has Codexis issued on next quarter's earnings?

Codexis issued an update on its FY 2021 earnings guidance on Thursday, June, 17th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $89 million-93 million, compared to the consensus revenue estimate of $83.74 million.

What price target have analysts set for CDXS?

5 analysts have issued 1 year target prices for Codexis' stock. Their forecasts range from $16.00 to $32.00. On average, they anticipate Codexis' share price to reach $26.60 in the next twelve months. This suggests a possible upside of 35.4% from the stock's current price.
View analysts' price targets for Codexis
or view top-rated stocks among Wall Street analysts.

Who are Codexis' key executives?

Codexis' management team includes the following people:
  • Mr. John J. Nicols, Pres, CEO & Director (Age 57, Pay $1.06M)
  • Mr. Ross Taylor Jr., M.B.A., Sr. VP & CFO (Age 58, Pay $471.53k)
  • Dr. Karl A. Schoene Ph.D., Sr. VP of Devel. & Operations
  • Dr. Gjalt Huisman Ph.D., Sr. VP of Strategic Devel. & GM of Biotherapeutics
  • Mr. Rob Wilson Ph.D., Sr. VP & GM of Performance Enzymes
  • Dr. Stefan Lutz Ph.D., Sr. VP of Research
  • Mr. Robert Sato M.B.A., Ph.D., Sr. VP of Pharmaceutical Devel., Quality & Regulatory
  • Prof. Gerhard N. Mayr, Special Advisor to the Board (Age 75)
  • Dr. Davinder Singh Brar, Special Advisor to the Board (Age 69)

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis CEO John J. Nicols on John J. Nicols has an approval rating of 68% among Codexis' employees.

Who are some of Codexis' key competitors?

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), (CGC), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Who are Codexis' major shareholders?

Codexis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (9.74%), Baillie Gifford & Co. (9.20%), BlackRock Inc. (7.95%), Gilder Gagnon Howe & Co. LLC (3.81%), Telemark Asset Management LLC (3.81%) and William Blair Investment Management LLC (3.65%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends for Codexis

Which institutional investors are selling Codexis stock?

CDXS stock was sold by a variety of institutional investors in the last quarter, including Telemark Asset Management LLC, Janus Henderson Group PLC, Millennium Management LLC, Goldman Sachs Group Inc., First Light Asset Management LLC, Union Square Park Capital Management LLC, Assenagon Asset Management S.A., and State of New Jersey Common Pension Fund D. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Dennis P Wolf, John J Nicols, and Patrick Y Yang.
View insider buying and selling activity for Codexis
or view top insider-selling stocks.

Which institutional investors are buying Codexis stock?

CDXS stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, BlackRock Inc., Pier Capital LLC, Nuveen Asset Management LLC, Morgan Stanley, William Blair Investment Management LLC, Dimensional Fund Advisors LP, and Castleark Management LLC. Company insiders that have bought Codexis stock in the last two years include John J Nicols, and Patrick Y Yang.
View insider buying and selling activity for Codexis
or or view top insider-buying stocks.

How do I buy shares of Codexis?

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $19.64.

How much money does Codexis make?

Codexis has a market capitalization of $1.27 billion and generates $69.06 million in revenue each year. The biotechnology company earns $-24,010,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does Codexis have?

Codexis employs 181 workers across the globe.

What is Codexis' official website?

The official website for Codexis is

Where are Codexis' headquarters?

Codexis is headquartered at 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.